Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Syntara Pauses SNT-9465 Trial Recruitment Over Skin Irritation

Syntara Limited (SNT) · Health care

SNT: $0.016 -15.79% · MC: $28M

Syntara has paused recruitment in its Phase 1b SNT-9465 scar study after reports of mild to moderate skin irritation among some participants. The company will review unblinded data before deciding whether to resume recruitment or discontinue the study, with the review expected to finish this quarter.

Source announcements: 2026-11-10 09:50 to 2026-11-10 09:50 Sydney time
Story updated 2026-11-10 09:53 Sydney time
SourcesSyntara Pauses SNT-9465 Phase 1b Recruitment
Comments